184 related articles for article (PubMed ID: 37834206)
1. Is HOXA5 a Novel Prognostic Biomarker for Uterine Corpus Endometrioid Adenocarcinoma?
Song C; Kim KB; Lee GS; Shin S; Kim B
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834206
[TBL] [Abstract][Full Text] [Related]
2. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.
Watari H; Xiong Y; Hassan MK; Sakuragi N
Gynecol Oncol; 2009 Jan; 112(1):229-34. PubMed ID: 19007976
[TBL] [Abstract][Full Text] [Related]
3. RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma.
Liu S; Lin M; Ji H; Ding J; Zhu J; Ma R; Meng F
Diagn Pathol; 2019 Jan; 14(1):7. PubMed ID: 30684972
[TBL] [Abstract][Full Text] [Related]
4. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Expression of Homeobox A5 in Endometrial Cancer on the mRNA and Protein Level.
Dziobek K; Oplawski M; Zmarzły N; Gabarek BO; Kiełbasiński R; Kiełbasiński K; Kieszkowski P; Talkowski K; Boroń D
Curr Pharm Biotechnol; 2020; 21(7):635-641. PubMed ID: 31880256
[TBL] [Abstract][Full Text] [Related]
6. Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.
Hotton J; Agopiantz M; Leroux A; Charra-Brunaud C; Marie B; Busby-Venner H; Morel O; Guéant JL; Vignaud JM; Battaglia-Hsu SF; Gauchotte G
Virchows Arch; 2018 Apr; 472(4):623-633. PubMed ID: 29243125
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma.
Mhawech-Fauceglia P; Walia S; Yessaian A; Machida H; Matsuo K; Lawrenson K
Pathology; 2018 Aug; 50(5):499-503. PubMed ID: 29891190
[TBL] [Abstract][Full Text] [Related]
8. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
Ouyang D; Li R; Li Y; Zhu X
J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
[TBL] [Abstract][Full Text] [Related]
9. HOXA5 indicates poor prognosis and suppresses cell proliferation by regulating p21 expression in non small cell lung cancer.
Zhang ML; Nie FQ; Sun M; Xia R; Xie M; Lu KH; Li W
Tumour Biol; 2015 May; 36(5):3521-31. PubMed ID: 25549794
[TBL] [Abstract][Full Text] [Related]
10. A novel long non-coding RNA from the HOXA6-HOXA5 locus facilitates colon cancer cell growth.
Saijo S; Kuwano Y; Tange S; Rokutan K; Nishida K
BMC Cancer; 2019 Jun; 19(1):532. PubMed ID: 31159758
[TBL] [Abstract][Full Text] [Related]
11. Correlation of high LAT1 expression with the prognosis of endometrioid carcinoma of the uterine corpus.
Sato K; Miyamoto M; Takano M; Tsuda H
Virchows Arch; 2020 Sep; 477(3):421-427. PubMed ID: 32144539
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
13. Homeobox gene expression profile indicates HOXA5 as a candidate prognostic marker in oral squamous cell carcinoma.
Rodini CO; Xavier FC; Paiva KB; De Souza Setúbal Destro MF; Moyses RA; Michaluarte P; Carvalho MB; Fukuyama EE; ; Tajara EH; Okamoto OK; Nunes FD
Int J Oncol; 2012 Apr; 40(4):1180-8. PubMed ID: 22227861
[TBL] [Abstract][Full Text] [Related]
14. Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus.
Ervine A; Leung S; Gilks CB; McCluggage WG
Histopathology; 2014 May; 64(6):840-6. PubMed ID: 24267480
[TBL] [Abstract][Full Text] [Related]
15. Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Edqvist PH; Huvila J; Forsström B; Talve L; Carpén O; Salvesen HB; Krakstad C; Grénman S; Johannesson H; Ljungqvist O; Uhlén M; Pontén F; Auranen A
Gynecol Oncol; 2015 Jun; 137(3):529-37. PubMed ID: 25858696
[TBL] [Abstract][Full Text] [Related]
16. DNMT3A/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The Cancer Genome Atlas.
He D; Wang X; Zhang Y; Zhao J; Han R; Dong Y
Chin Med J (Engl); 2019 Jan; 132(2):161-170. PubMed ID: 30614867
[TBL] [Abstract][Full Text] [Related]
17. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
18. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
19. Cleaved caspase-3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology.
Ogane N; Yasuda M; Kato H; Kato T; Yano M; Kameda Y; Kamoshida S
Cytopathology; 2018 Jun; 29(3):254-261. PubMed ID: 29626374
[TBL] [Abstract][Full Text] [Related]
20. Genetic features of endometrioid-type endometrial carcinoma arising in uterine adenomyosis.
Yoshida H; Asami Y; Kobayashi-Kato M; Tanase Y; Uno M; Ishikawa M; Shiraishi K; Kato T
Virchows Arch; 2022 Jul; 481(1):117-123. PubMed ID: 34791535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
